|
Home : Unsafe Drugs : Avandia : Newsfeeds : Rise in GlaxoSmithKline Profits Rise in GlaxoSmithKline Profits
GSK was rocked in September when the EU medicines regulator decided to pull its former diabetes product Avandia off the shelves over fears that it increased the risk of heart attack and strokes. Savings from a major cost-cutting programme and asset ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




